These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 29522576)

  • 1. Rapid and easy detection of low-level resistance to vancomycin in methicillin-resistant Staphylococcus aureus by matrix-assisted laser desorption ionization time-of-flight mass spectrometry.
    Asakura K; Azechi T; Sasano H; Matsui H; Hanaki H; Miyazaki M; Takata T; Sekine M; Takaku T; Ochiai T; Komatsu N; Shibayama K; Katayama Y; Yahara K
    PLoS One; 2018; 13(3):e0194212. PubMed ID: 29522576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid Detection of Vancomycin-Intermediate Staphylococcus aureus by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry.
    Mather CA; Werth BJ; Sivagnanam S; SenGupta DJ; Butler-Wu SM
    J Clin Microbiol; 2016 Apr; 54(4):883-90. PubMed ID: 26763961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012-2013.
    Huang SH; Chen YC; Chuang YC; Chiu SK; Fung CP; Lu PL; Wang LS; Wu TL; Wang JT
    J Microbiol Immunol Infect; 2016 Oct; 49(5):701-707. PubMed ID: 26320398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for Intermediately Vancomycin-Susceptible and Vancomycin-Heteroresistant Staphylococcus aureus by Use of Vancomycin-Supplemented Brain Heart Infusion Agar Biplates: Defining Growth Interpretation Criteria Based on Gold Standard Confirmation.
    Khatib R; Riederer K; Sharma M; Shemes S; Iyer SP; Szpunar S
    J Clin Microbiol; 2015 Nov; 53(11):3543-6. PubMed ID: 26311860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
    Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
    J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Prevalence of Vancomycin-Intermediate Staphylococcus aureus and Heterogeneous VISA Among Methicillin-Resistant Strains Isolated from Pediatric Population in a Turkish University Hospital.
    Mirza HC; Sancak B; Gür D
    Microb Drug Resist; 2015 Oct; 21(5):537-44. PubMed ID: 25919019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid Detection of Heterogeneous Vancomycin-Intermediate
    Wang HY; Chen CH; Lee TY; Horng JT; Liu TP; Tseng YJ; Lu JJ
    Front Microbiol; 2018; 9():2393. PubMed ID: 30364336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The incidence and risk factors for heterogeneous vancomycin intermediate Staphylococcus aureus].
    Feng NN; Wang Q; Song YL; He LX; Zhou CM; Xie HM; Li HY
    Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):318-22. PubMed ID: 23925360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Investigation of the VISA and hVISA Presence in Methicillin-Resistant Staphylococcus aureus Isolates by Various Methods].
    Uçar Ş; Duman Y; Tanrıverdi ES; Tekerekoğlu MS; Otlu B
    Mikrobiyol Bul; 2022 Oct; 56(4):593-605. PubMed ID: 36458707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of vancomycin and teicoplanin disk diffusion test in isogenic vancomycin non-susceptible Staphylococcus aureus.
    Wongthong S; Dutchanutouch K; Namsaengkang V; Chanawong A; Wilailuckana C; Lulitanond A
    J Infect Dev Ctries; 2015 Feb; 9(2):157-64. PubMed ID: 25699490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo development of daptomycin resistance in vancomycin-susceptible methicillin-resistant Staphylococcus aureus severe infections previously treated with glycopeptides.
    Capone A; Cafiso V; Campanile F; Parisi G; Mariani B; Petrosillo N; Stefani S
    Eur J Clin Microbiol Infect Dis; 2016 Apr; 35(4):625-31. PubMed ID: 26815434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate Staphylococcus aureus in meticillin-resistant S. aureus bacteraemia patients.
    Wang JL; Lai CH; Lin HH; Chen WF; Shih YC; Hung CH
    Int J Antimicrob Agents; 2013 Nov; 42(5):390-4. PubMed ID: 24041465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced vancomycin susceptibility found in methicillin-resistant and methicillin-sensitive Staphylococcus aureus clinical isolates in Northeast China.
    Hu J; Ma XX; Tian Y; Pang L; Cui LZ; Shang H
    PLoS One; 2013; 8(9):e73300. PubMed ID: 24069184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attenuated total reflection: Fourier transform infrared spectroscopy for detection of heterogeneous vancomycin-intermediate Staphylococcus aureus.
    Wongthong S; Tippayawat P; Wongwattanakul M; Poung-Ngern P; Wonglakorn L; Chanawong A; Heraud P; Lulitanond A
    World J Microbiol Biotechnol; 2020 Jan; 36(2):22. PubMed ID: 31955251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide biomarker discovery for identification of methicillin-resistant and vancomycin-intermediate Staphylococcus aureus strains by MALDI-TOF.
    Lu JJ; Tsai FJ; Ho CM; Liu YC; Chen CJ
    Anal Chem; 2012 Jul; 84(13):5685-92. PubMed ID: 22762263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibiotic susceptibility survey of blood-borne MRSA isolates in Japan from 2008 through 2011.
    Hanaki H; Cui L; Ikeda-Dantsuji Y; Nakae T; Honda J; Yanagihara K; Takesue Y; Matsumoto T; Sunakawa K; Kaku M; Tomono K; Fukuchi K; Kusachi S; Mikamo H; Takata T; Otsuka Y; Nagura O; Fujitani S; Aoki Y; Yamaguchi Y; Tateda K; Kadota J; Kohno S; Niki Y
    J Infect Chemother; 2014 Sep; 20(9):527-34. PubMed ID: 25066429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic characteristics and comparative proteomics of Staphylococcus aureus strains with different vancomycin-resistance levels.
    Sirichoat A; Lulitanond A; Kanlaya R; Tavichakorntrakool R; Chanawong A; Wongthong S; Thongboonkerd V
    Diagn Microbiol Infect Dis; 2016 Dec; 86(4):340-344. PubMed ID: 27717648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of heterogeneous vancomycin intermediate resistance in MRSA isolates from Latin America.
    Castro BE; Berrio M; Vargas ML; Carvajal LP; Millan LV; Rios R; Hernandez AK; Rincon S; Cubides P; Forero E; Dinh A; Seas C; Munita JM; Arias CA; Reyes J; Diaz L
    J Antimicrob Chemother; 2020 Sep; 75(9):2424-2431. PubMed ID: 32562543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular epidemiology and clinical characteristics of hetero-resistant vancomycin intermediate Staphylococcus aureus bacteremia in a Taiwan Medical Center.
    Lin SY; Chen TC; Chen FJ; Chen YH; Lin YI; Siu LK; Lu PL
    J Microbiol Immunol Infect; 2012 Dec; 45(6):435-41. PubMed ID: 22749725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic effect of vancomycin combined with cefotaxime, imipenem, or meropenem against Staphylococcus aureus with reduced susceptibility to vancomycin.
    Srisrattakarn A; Chaiyapoke C; Booncharoen S; Wongthong S; Chanawong A; Tippayawat P; Tavichakorntrakool R; Lulitanond A
    Turk J Med Sci; 2021 Aug; 51(4):2150-2158. PubMed ID: 33705643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.